Effects of tyrosine kinase inhibition on bone metabolism: Untargeted consequences of targeted therapies

Endocrine-Related Cancer

Volumn 21, Issue 3, 2014, Pages

  Alemán, José O ^a   Farooki, Azeez ^a   Girotra, Monica ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Bone; Calcium; Metastasis; Parathyroid hormone; Tyrosine kinase inhibitor

Indexed keywords

BCR ABL PROTEIN; BCR ABL PROTEIN INHIBITOR; CABOZANTINIB; COLONY STIMULATING FACTOR 1; DASATINIB; DENOSUMAB; IMATINIB; PLATELET DERIVED GROWTH FACTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; REARRANGED DURING TRANSFECTION INHIBITOR; RET KINASE; SARACATANIB; SORAFENIB; SUNITINIB; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; PROTEIN KINASE INHIBITOR;

ABSENCE OF SIDE EFFECTS; ADVANCED CANCER; BONE MASS; BONE METABOLISM; BONE METASTASIS; BONE MINERAL; CASTRATION RESISTANT PROSTATE CANCER; CELL ACTIVITY; CELL MATURATION; CHRONIC MYELOID LEUKEMIA; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; FANCONI RENOTUBULAR SYNDROME; GASTROINTESTINAL STROMAL TUMOR; HEMATOPOIETIC STEM CELL; HUMAN; HYPERPARATHYROIDISM; HYPOCALCEMIA; HYPOPHOSPHATEMIA; JAW OSTEONECROSIS; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; MESENCHYMAL STEM CELL; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; ONCOGENE RET; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; OSTEOSARCOMA; PANCREATIC NEUROENDOCRINE TUMOR; PHOSPHATE METABOLISM; PHOSPHATURIA; QT PROLONGATION; REVIEW; SARCOPENIA; SECONDARY HYPERPARATHYROIDISM; SOLID TUMOR; THYROID CARCINOMA; THYROID MEDULLARY CARCINOMA; TORSADE DES POINTES; ANTAGONISTS AND INHIBITORS; BONE; DRUG EFFECTS; METABOLISM; PREVENTION AND CONTROL;

BONE AND BONES; BONE RESORPTION; HUMANS; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES;

EID: 84903600991     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-12-0400     Document Type: Review

References (67)

1. Agrillo A, Nastro Siniscalchi E, Facchini A, Filiaci F & Ungari C 2012 Osteonecrosis of the jaws in patients assuming bisphosphonates and sunitinib: two case reports. European Review for Medical and Pharmacological Sciences 16 952-957.
2. Albiges L, Oudard S,Negrier S, Caty A, GravisG, Joly F, Duclos B,Geoffrois L, Rolland F, Guillot A et al. 2012 Complete remission with tyrosine kinase inhibitors in renal cell carcinoma. Journal of Clinical Oncology 30 482-487. (doi:10.1200/JCO.2011.37.2516)
3. Ando W, Hashimoto J, Nampei A, Tsuboi H, Tateishi K, Ono T, NakamuraN, Ochi T & Yoshikawa H 2006 Imatinib mesylate inhibits osteoclastogenesis and joint destruction in rats with collagen-induced arthritis (CIA). Journal of Bone and Mineral Metabolism 24 274-282. (doi:10.1007/s00774-006-0684-1) (Pubitemid 43992670)
4. Antoun S, Birdsell L, Sawyer MB, Venner P, Escudier B & Baracos VE 2010 Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study. Journal of Clinical Oncology 28 1054-1060. (doi:10.1200/JCO.2009.24.9730)
5. Baldazzi V, Tassi R, Lapini A, Lunghi A, Garofoli E, Caruso S, Carini M & Mazzanti R 2012 Sunitinib-induced hyperparathyroidism: a possible mechanism to altered bone homeostasis. Cancer 118 3165-3172. (doi:10.1002/cncr.26435)
6. Berman E, Nicolaides M, Maki RG, Fleisher M, Chanel S, Scheu K, Wilson BA, Heller G & Sauter NP 2006 Altered bone and mineral metabolism in patients receiving imatinib mesylate. New England Journal of Medicine 354 2006-2013. (doi:10.1056/NEJMoa051140)
7. Berman E, Girotra M, Cheng C, Chanel S, Maki R, Shelat M, Strauss HW, Fleisher M, Heller G & Farooki A 2013 Effect of long term imatinib on bone in adults with chronic myelogenous leukemia and gastrointestinal stromal tumors. Leukemia Research 37 790-794. (doi:10.1016/j.leukres.2013.02.005)
8. Berruti A, Cook R, Saad F, Buttigliero C, Lipton A, Tampellini M, Lee KA, Coleman RE & Smith MR 2012 Prognostic role of serum parathyroid hormone levels in advanced prostate cancer patients undergoing zoledronic acid administration. Oncologist 17 645-652. (doi:10.1634/theoncologist.2011-0448)
9. Beuselinck B, Wolter P, Karadimou A, Elaidi R, Dumez H, Rogiers A, Van Cann T, Willems L, Body JJ, Berkers J et al. 2012 Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases. British Journal of Cancer 107 1665-1671. (doi:10.1038/bjc.2012.385)
10. Bilik D, McEwen LN, Brown MB, Pomeroy NE, Kim C, Asao K, Crosson JC, Duru OK, Ferrara A, Hsiao VC et al. 2010 Thiazolidinediones and fractures: evidence from translating research into action for diabetes. Journal of Clinical Endocrinology and Metabolism 95 4560-4565. (doi:10.1210/jc.2009-2638)
11. Borriello A, Caldarelli I, Basile MA, Bencivenga D, Tramontano A, Perrotta S, Della Ragione F & Oliva A 2011 The tyrosine kinase inhibitor dasatinib induces a marked adipogenic differentiation of human multipotent mesenchymal stromal cells. PLoS ONE 6 e28555. (doi:10.1371/journal.pone.0028555)
12. Brassard M, Neraud B, Trabado S, Salenave S, Brailly-Tabard S, Borget I, Baudin E, Leboulleux S, Chanson P, Schlumberger M et al. 2011 Endocrine effects of the tyrosine kinase inhibitor vandetanib in patients treated for thyroid cancer. Journal of Clinical Endocrinology and Metabolism 96 2741-2749. (doi:10.1210/jc.2010-2771)
13. Buchdunger E, Zimmermann J, Mett H, Meyer T, Müller M, Druker BJ & Lydon NB 1996 Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Research 56 100-104.
14. Cabanillas ME, Waguespack SG, Bronstein Y, Williams MD, Feng L, Hernandez M, Lopez A, Sherman SI & Busaidy NL 2010 Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience. Journal of Clinical Endocrinology and Metabolism 95 2588-2595. (doi:10.1210/jc.2009-1923)
15. Chen HT, Tsou HK, Chang CH & Tang CH 2012 Hepatocyte growth factor increases osteopontin expression in human osteoblasts through PI3K, Akt, c-Src, and AP-1 signaling pathway. PLoS ONE 7 e38378. (doi:10.1371/journal.pone. 0038378)
16. Cher ML, Towler DA, Rafii S, Rowley D, Donahue HJ, Keller E, Herlyn M, Cho EA & Chung LW 2006 Cancer interaction with the bone microenvironment: a workshop of the National Institutes of Health Tumor Microenvironment Study Section. American Journal of Pathology 168 1405-1412. (doi:10.2353/ajpath.2006. 050874)
17. Dai J, Zhang H, Karatsinides A, Keller JM, Kozloff K, Aftab DT, Schimmoller F & Keller ET 2013 Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions. Clinical Cancer Research 20 617-630.
18. Dayyani F, Gallick GE, Logothetis CJ & Corn PG 2011 Novel therapies for metastatic castrate-resistant prostate cancer. Journal of the National Cancer Institute 103 1665-1675. (doi:10.1093/jnci/djr362)
19. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA et al. 2006 Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368 1329-1338. (doi:10.1016/S0140-6736(06)69446-4) (Pubitemid 44528723)
20. Dewar AL, Cambareri AC, Zannettino ACW, Miller BL, Doherty KV, Hughes TP & Lyons AB 2005 Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood 105 3127-3132. (doi:10.1182/blood-2004-10-3967)
21. Dror Michaelson M, Regan MM, Oh WK, Kaufman DS, Olivier K, Michaelson SZ, Spicer B, Gurski C, Kantoff PW & Smith MR 2009 Phase II study of sunitinib in men with advanced prostate cancer. Annals of Oncology 20 913-920. (doi:10.1093/annonc/mdp111)
22. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J & Lydon NB 1996 Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature Medicine 2 561-566. (doi:10.1038/nm0596-561)
23. El Hajj Dib I, Gallet M, Mentaverri R, Sévenet N, Brazier M & Kamel S 2006 Imatinib mesylate (Gleevec) enhances mature osteoclast apoptosis and suppresses osteoclast bone resorbing activity. European Journal of Pharmacology 551 27-33. (doi:10.1016/j.ejphar.2006.09.007) (Pubitemid 44648069)
24. Fitter S, Dewar AL, Kostakis P, To LB, Hughes TP, Roberts MM, Lynch K, Vernon-Roberts B & Zannettino ACW 2008 Long-term imatinib therapy promotes bone formation in CML patients. Blood 111 2538-2547. (doi:10.1182/blood-2007-07- 104281)
25. François H, Coppo P, Hayman JP, Fouqueray B, Mougenot B & Ronco P 2008 Partial Fanconi syndrome induced by imatinib therapy: a novel cause of urinary phosphate loss. American Journal of Kidney Diseases 51 298-301. (doi:10.1053/j.ajkd.2007.10.039)
26. Garcia-Gomez A, Ocio EM, Crusoe E, Santamaria C, Hernández-Campo P, Blanco JF, Sanchez-Guijo FM, Hernández-Iglesias T, Briñón JG, Fisac-Herrero RM et al. 2012 Dasatinib as a bone-modifying agent: anabolic and anti-resorptive effects. PLoS ONE 7 e34914. (doi:10.1371/journal.pone. 0034914)
27. Gattei V, Celetti A, Cerrato A, DeganM, De Iuliis A, Rossi FM, Chiappetta G, Consales C, Improta S, Zagonel V et al. 1997 Expression of the RET receptor tyrosine kinase and GDNFR-a in normal and leukemic human hematopoietic cells and stromal cells of the bone marrow microenvironment. Blood 89 2925-2937. (Pubitemid 27172580)
28. Goodkin DA & Pierce GF 1993 Role of platelet-derived growth factor in osteoblast function and bone synthesis. Wound Repair and Regeneration 1 203-212. (doi:10.1046/j.1524-475X.1993.10405.x)
29. Grignani G, Palmerini E, Dileo P, Asaftei SD, D'Ambrosio L, Pignochino Y, Mercuri M, Picci P, Fagioli F, Casali PG et al. 2012 A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. Annals of Oncology 23 508-516. (doi:10.1093/annonc/mdr151)
30. Hannon RA, Clack G, Rimmer M, Swaisland A, Lockton JA, Finkelman RD & Eastell R 2010 Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: a randomized, double-blind, placebocontrolled, multiple-ascending-dose phase I trial. Journal of Bone and Mineral Research 25 463-471. (doi:10.1359/jbmr.090830)
31. Hannon RA, Finkelman RD, Clack G, Iacona RB, Rimmer M, Gossiel F, Baselga J & Eastell R 2012 Effects of Src kinase inhibition by saracatinib (AZD0530) on bone turnover in advanced malignancy in a phase I study. Bone 50 885-892. (doi:10.1016/j.bone.2011.12.017)
32. Hock JM 1994 Platelet-derived growth factor enhances bone cell replication, but not differentiated function of osteoblasts. Endocrinology 134 1423-1428. (Pubitemid 24085600)
33. Horowitz MC, Coleman DL, Flood PM, Kupper TS & Jilka RL 1989 Parathyroid hormone and lipopolysaccharide induce murine osteoblast-like cells to secrete a cytokine indistinguishable from granulocytemacrophage colony-stimulating factor. Journal of Clinical Investigation 83 149-157. (doi:10.1172/JCI113852) (Pubitemid 19048417)
34. Huang EJ, Nocka KH, Buck J & Besmer P 1992 Differential expression and processing of two cell associated forms of the kit-ligand: KL-1 and KL-2. Molecular Biology of the Cell 3 349-362. (doi:10.1091/mbc.3.3.349) (Pubitemid 23095970)
35. Ianotto JC, Tempescul A, Amet Y, Grall P, Dalbies F, Eveillard JR, Guillerm G & Berthou C 2012 Imatinib mesylate induces massive and nonspecific aminoaciduria in CML patients. American Journal of Hematology 87 437-439. (doi:10.1002/ajh.23113)
36. Id Boufker H, Lagneaux L, Najar M, Piccart M, Ghanem G, Body JJ & Journé F 2010 The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblasts. BMC Cancer 10 298. (doi:10.1186/1471-2407-10-298)
37. IOM 2011 In Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC, USA: National Academies Press.
38. Jönsson S, Hjorth-Hansen H, Olsson B,Wadenvik H, Sundan A & Standal T 2012 Imatinib inhibits proliferation of human mesenchymal stem cells and promotes early but not late osteoblast differentiation in vitro. Journal of Bone and Mineral Metabolism 30 119-123. (doi:10.1007/s00774-011-0323-3)
39. Kebebew E, Ituarte PH, Siperstein AE, Duh QY & Clark OH 2000 Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer 88 1139-1148. (doi:10.1002/(SICI)1097-0142(20000301)88:5〈1139::AID-CNCR26〉3.0. CO;2-Z) (Pubitemid 30127676)
40. Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R, Pfister DG, Cohen EE, Janisch L, Nauling F et al. 2011 Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. Journal of Clinical Oncology 29 2660-2666. (doi:10.1200/JCO. 2010.32.4145)
41. Lam ET, Ringel MD, Kloos RT, Prior TW, Knopp MV, Liang J, Sammet S, Hall NC, Wakely PE, Vasko VV et al. 2010 Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. Journal of Clinical Oncology 28 2323-2330. (doi:10.1200/JCO.2009.25.0068)
42. Lang T, Streeper T, Cawthon P, Baldwin K, Taaffe DR & Harris TB 2010 Sarcopenia: etiology, clinical consequences, intervention, and assessment. Osteoporosis International 21 543-559. (doi:10.1007/s00198-009-1059-y)
43. Maes C, Carmeliet G & Schipani E 2012 Hypoxia-driven pathways in bone development, regeneration and disease. Nature Reviews. Rheumatology 8 358-366. (doi:10.1038/nrrheum.2012.36)
44. Maita S, Yuasa T, Tsuchiya N, Mitobe Y, Narita S, Horikawa Y, Hatake K, Fukui I, Kimura S, Maekawa T & Habuchi T 2012 Antitumor effect of sunitinib against skeletal metastatic renal cell carcinoma through inhibition of osteoclast function. International Journal of Cancer 130 677-684. (doi:10.1002/ijc.26034)
45. Motzer RJ, Hutson TE, Olsen MR, Hudes GR, Burke JM, Edenfield WJ, Wilding G, Agarwal N, Thompson JA, Cella D et al. 2012 Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. Journal of Clinical Oncology 30 1371-1377. (doi:10.1200/JCO.2011.36.4133)
46. Murray RM, Grill V, Crinis N, Ho PW, Davison J & Pitt P 2001 Hypocalcemic and normocalcemic hyperparathyroidism in patients with advanced prostatic cancer. Journal of Clinical Endocrinology and Metabolism 86 4133-4138. (doi:10.1210/jcem.86.9.7864) (Pubitemid 32848525)
47. O'Sullivan S, Naot D, Callon K, Porteous F, Horne A, Wattie D, Watson M, Cornish J, Browett P & Grey A 2007 Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms. Journal of Bone and Mineral Research 22 1679-1689. (doi:10.1359/jbmr.070719) (Pubitemid 351235134)
48. O'Sullivan S, Horne A, Wattie D, Porteous F, Callon K, Gamble G, Ebeling P, Browett P & Grey A 2009 Decreased bone turnover despite persistent secondary hyperparathyroidism during prolonged treatment with imatinib. Journal of Clinical Endocrinology and Metabolism 94 1131-1136. (doi:10.1210/jc.2008- 2324)
49. O'Sullivan S, Naot D, Callon KE, Watson M, Gamble GD, Ladefoged M, Karsdal MA, Browett P, Cornish J & Grey A 2011 Imatinib mesylate does not increase bone volume in vivo. Calcified Tissue International 88 16-22. (doi:10.1007/s00223-010-9429-1)
50. Pausova Z, Soliman E, Amizuka N, Janicic N, Konrad EM, Arnold A, Goltzman D & Hendy GN 1996 Role of the RET proto-oncogene in sporadic hyperparathyroidism and in hyperparathyroidism of multiple endocrine neoplasia type 2. Journal of Clinical Endocrinology and Metabolism 81 2711-2718. (Pubitemid 26240300)
51. Pittas AG, Adler M, Fazzari M, Tickoo S, Rosai J, Larson SM & Robbins RJ 2000 Bone metastases from thyroid carcinoma: clinical characteristics and prognostic variables in one hundred forty-six patients. Thyroid 10 261-268. (doi:10.1089/thy.2000.10.261) (Pubitemid 30202413)
52. Sahi C, Knox JJ, Hinder V, Deva S, Cole D & Clemons MBR 2009 The effects of sorafenib and sunitinib on bone turnover markers in patients with bone metastases from renal cell carcinoma. American Society of Clinical Oncology 27 (supplement) e16145.
53. Schabel SI, Tyminski L, Holland RD & Rittenberg GM 1980 The skeletal manifestations of chronic myelogenous leukemia. Skeletal Radiology 5 145-149. (doi:10.1007/BF00347255) (Pubitemid 10064625)
54. Schipani E, Maes C, Carmeliet G & Semenza GL 2009 Regulation of osteogenesis-angiogenesis coupling by HIFs and VEGF. Journal of Bone and Mineral Research 24 1347-1353. (doi:10.1359/jbmr.090602)
55. Sherman SI 2009 Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers. Journal of Clinical Endocrinology and Metabolism 94 1493-1499. (doi:10.1210/jc.2008-0923)
56. Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS et al. 2013 Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. Journal of Clinical Oncology 31 412-419. (doi:10.1200/JCO.2012.45.0494)
57. Soriano P, Montgomery C, Geske R & Bradley A 1991 Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 64 693-702. (doi:10.1016/0092-8674(91)90499-O) (Pubitemid 121001157)
58. Steingrímsson E, Moore KJ, Lamoreux ML, Ferré- D'Amaré AR, Burley SK, Zimring DC, Skow LC, Hodgkinson CA, Arnheiter H & Copeland NG 1994 Molecular basis of mouse microphthalmia (mi) mutations helps explain their developmental and phenotypic consequences. Nature Genetics 8 256-263. (doi:10.1038/ng1194-256) (Pubitemid 24338737)
59. Towler DA 2003 Angiogenesis and marrow stromal cell fates: roles in bone strength. Osteoporosis International 14 (Suppl 5) S46-S50 (discussion S50-S53). (doi:10.1007/s00198-003-1473-5)
60. Vandyke K, Fitter S, Dewar AL, Hughes TP & Zannettino ACW 2010a Dysregulation of bone remodeling by imatinib mesylate. Blood 115 766-774. (doi:10.1182/blood-2009-08-237404)
61. Vandyke K, Dewar AL, Diamond P, Fitter S, Schultz CG, Sims NA & Zannettino ACW 2010b The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivo. Journal of Bone and Mineral Research 25 1759-1770. (doi:10.1002/jbmr.85)
62. Vandyke K, Fitter S, Drew J, Fukumoto S, Schultz CG, Sims NA, Yeung DT, Hughes TP& Zannettino ACW2012 Prospective histomorphometric and DXA evaluation of bone remodeling in imatinib-treated CML patients: evidence for site-specific skeletal effects. Journal of Clinical Endocrinology and Metabolism 98 67-76. (doi:10.1210/jc.2012-2426)
63. Wells SA, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR et al. 2012 Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. Journal of Clinical Oncology 30 134-141. (doi:10.1200/JCO.2011. 35.5040)
64. Yang K-H, Park S-Y, Park S-W, Lee S-H, Han S-B, Jung W-K & Kim S-J 2010 Insufficient bilateral femoral subtrochanteric fractures in a patient receiving imatinib mesylate. Journal of Bone and Mineral Metabolism 28 713-718. (doi:10.1007/s00774-010-0203-2)
65. Yu EY, Massard C, Gross ME, Carducci MA, Culine S, Hudes G, Posadas EM, Sternberg CN, Wilding G, Trudel GC et al. 2011 Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer. Urology 77 1166-1171. (doi:10.1016/j.urology.2011.01.006)
66. Zelzer E, McLean W, Ng Y-S, Fukai N, Reginato AM, Lovejoy S, D'Amore PA & Olsen BR 2002 Skeletal defects in VEGF(120/120) mice reveal multiple roles for VEGF in skeletogenesis. Development 129 1893-1904. (Pubitemid 34874204)
67. Zhang Z, Chen J & Jin D 1998 Platelet-derived growth factor (PDGF)-BB stimulates osteoclastic bone resorption directly: the role of receptor b. Biochemical and Biophysical Research Communications 251 190-194. (doi:10.1006/bbrc.1998.9412) (Pubitemid 28498084)